Clinical Trial Update: Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation Phase 1/2 trial of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa has completed, and results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• KB001

Snippet

Sponsor: Humanigen, Inc. | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2011-08-08